Skyhawk Therapeutics nabs Peloton exec and cancer R&D veteran as VP of oncology biology
July 08, 2019 / Ben Adams
Two months after Merck announced a billion-dollar-plus deal to buy out late-stage cancer biotech Peloton, some of its staffers are finding new homes. This is good news for RNA startup Skyhawk Therapeutics, which has nabbed Peloton’s former VP of biology, Dr. Tai Wong, as its own VP of oncology biology. At Peloton, he led the team that was responsible for the early-stage work on its assets targeting hypoxia-inducible factor-2α in cancer, as well as other oncology programs in Peloton's exploratory pipeline. Wong, who leaves the biotech as it becomes subsumed under Merck, also served a major 19-year stint at Bristol-Myers Squibb, most recently as its group director in oncology drug discovery. “Dr. Tai Wong brings a strong track record of preclinical and translational oncology biology experience to Skyhawk,” said Kathleen McCarthy, co-founder and CSO of Skyhawk Therapeutics.